In the last trading session, 8.95 million Artiva Biotherapeutics Inc (NASDAQ:ARTV) shares changed hands as the company’s beta touched 0. With the company’s per share price at $3.31 changed hands at $0.87 or 35.66% during last session, the market valuation stood at $80.65M. ARTV’s last price was a discount, traded about -422.96% off its 52-week high of $17.31. The share price had its 52-week low at $2.29, which suggests the last value was 30.82% up since then. When we look at Artiva Biotherapeutics Inc’s average trading volume, we note the 10-day average is 0.97 million shares, with the 3-month average coming to 98.27K.
Artiva Biotherapeutics Inc (NASDAQ:ARTV) trade information
Instantly ARTV was in green as seen at the end of in last trading. With action 10.33%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -67.16%, with the 5-day performance at 10.33% in the green. However, in the 30-day time frame, Artiva Biotherapeutics Inc (NASDAQ:ARTV) is -38.25% down. Looking at the short shares, we see there were 0.85 million shares sold at short interest cover period of 9.98 days.
The consensus price target for the stock as assigned by Wall Street analysts is 20.5, meaning bulls need an upside of 83.85% from its current market value. According to analyst projections, ARTV’s forecast low is 18 with 23 as the target high. To hit the forecast high, the stock’s price needs a -594.86% plunge from its current level, while the stock would need to soar -443.81% for it to hit the projected low.
Artiva Biotherapeutics Inc (ARTV) estimates and forecasts
Year-over-year growth is forecast to reach -100.00% down from the last financial year.
The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -64.01%. The 2025 estimates are for Artiva Biotherapeutics Inc earnings to increase by 49.54%, but the outlook for the next 5-year period is at 21.09% per year.
ARTV Dividends
Artiva Biotherapeutics Inc is expected to release its next quarterly earnings report on 2025-Mar-23.
Artiva Biotherapeutics Inc (NASDAQ:ARTV)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 22.63% of Artiva Biotherapeutics Inc shares while 90.85% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 117.42%.
Among Mutual Funds, the top two as of Dec 31, 2024 were SMALLCAP WORLD FUND INC and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 915.39 shares estimated at $3.03 million under it, the former controlled 3.76% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.22% of the shares, roughly 540.17 shares worth around $1.79 million.
